LABA/LAMAs set to overtake ICS/LABAs in non-exacerbating COPD patients.
By Astrid Kurniawan, Analyst
15 May 2016
I am an analyst for the market access and strategy team at Datamonitor Healthcare, where my aim is to provide an analysi...
Read full bio
Long-acting beta 2 agonist (LABA)/long acting muscarinic antagonist (LAMA) combination inhalers are gaining traction and are likely to replace inhaled corticosteroid (ICS)/LABAs as the preferred treatment for Stage II and Stage III patients in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. There is growing evidence that LABA/LAMAs are more appropriate for non-exacerbating patients compared to ICS/LABAs. Anoro (umeclidinium/vilanterol; GlaxoSmithKline) and Utibron (indacaterol/glycopyrronium; Novartis/Pfizer), which is marketed as Ultibro in the EU, exhibited superior efficacy in head-to-head trials against Advair DPI in COPD patients who have not had moderate to severe exacerbations in the past 12 months. Datamonitor Healthcare believes that current treatment guidelines could change to include treatment with LABA/LAMA combinations before the addition of an ICS for patients who remain symptomatic but who are not exacerbators. Such a change would strongly benefit the LABA/LAMA class as a whole, further driving uptake.
“There is a lot more evidence now that LABA/LAMA is at least as good as LABA/ICS and possibly better. So, the order in which you might pick them – currently [the National Institute for Health and Care Excellence] says that you should consider LABA/LAMA if ICS is not indicated or not tolerated, whereas I think now, LABA/LAMAs would be probably the first choice in most cases.” –UK payer-advising key opinion leader
Get your free demo today – simply fill out the form to the right.